High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions

Abstract Functional bivalent miniantibodies, directed against the epidermal growth factor receptor, accumulated to more than 3 gl−1 in high-cell-density cultures of Escherichia coli RV308(pHKK) on a pilot scale. The miniantibodies consist of scFv fragments with a C-termi-nal hinge followed by a helix-turn-helix motif, which homodimerizes in vivo. The improved expression vector pHKK is characterized by the hok/sok suicide system, improving plasmid maintenance, and the inducible lac p/o promoter system with the very strong T7g10 Shine-Dalgarno sequence. The expression unit is flanked by terminators. The prototrophic RV308 cells were cultivated in glucose mineral salt medium and reached a cell density of 145 g dry biomass l−1 after 33 h. After induction, growth continued almost unchanged for a further 4 h with concomitant miniantibody formation. In the fed-batch phase, the concentration of glucose was kept almost constant at the physiological level of approximately 1.5 g l−1, using on-line flow injection analysis for control. Surprisingly, E. coli RV308(pHKK) did not accumulate significant amounts of the metabolic by-product acetate under these unlimited aerobic growth conditions.

[1]  R. R. Robinson,et al.  Escherichia coli secretion of an active chimeric antibody fragment. , 1988, Science.

[2]  A. Plückthun,et al.  Tetravalent miniantibodies with high avidity assembling in Escherichia coli. , 1995, Journal of molecular biology.

[3]  A. Plückthun,et al.  Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. , 1988, Science.

[4]  R. Glockshuber,et al.  The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli. , 1992, Biochemistry.

[5]  J. Huston,et al.  Medical applications of single-chain antibodies. , 1993, International reviews of immunology.

[6]  M. Fanger,et al.  Bispecific antibodies. , 1992, Critical reviews in immunology.

[7]  W. Deckwer,et al.  High cell density cultivation of Escherichia coli at controlled specific growth rate. , 1991, Journal of biotechnology.

[8]  A. Plückthun,et al.  Functional antibody single-chain fragments from the cytoplasm of Escherichia coli: influence of thioredoxin reductase (TrxB). , 1995, Gene.

[9]  E. Haber,et al.  Engineered Antibodies as Pharmacological Tools , 1992, Immunological reviews.

[10]  A. Plückthun,et al.  Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. , 1992, Biochemistry.

[11]  E. Haber,et al.  Protein engineering of single-chain Fv analogs and fusion proteins. , 1991, Methods in enzymology.

[12]  R. Turner,et al.  An autoclavable glucose biosensor for microbial fermentation monitoring and control , 1995, Biotechnology and bioengineering.

[13]  R. Rudolph,et al.  Renaturation, Purification and Characterization of Recombinant Fab-Fragments Produced in Escherichia coli , 1991, Bio/Technology.

[14]  N. Thornhill,et al.  Closed‐loop control of fed‐batch cultures of recombinant Escherichia coli using on‐line HPLC , 1994, Biotechnology and bioengineering.

[15]  U. K. Laemmli,et al.  Cleavage of structural proteins during , 1970 .

[16]  G W Luli,et al.  A predictive and feedback control algorithm maintains a constant glucose concentration in fed-batch fermentations , 1991, Applied and environmental microbiology.

[17]  K. Gerdes,et al.  Mechanism of post‐segregational killing: translation of Hok, SrnB and Pnd mRNAs of plasmids R1, F and R483 is activated by 3′‐end processing. , 1994, The EMBO journal.

[18]  A. Plückthun,et al.  Improved Bivalent Miniantibodies, with Identical Avidity as Whole Antibodies, Produced by High Cell Density Fermentation of Escherichia coli , 1993, Nature Biotechnology.

[19]  U. Rinas,et al.  Simple fed-batch technique for high cell density cultivation of Escherichia coli. , 1995, Journal of biotechnology.

[20]  J. Oelze Wachstum von Mikroorganismen. Experimente und Modelle. Von Friedrich Bergter. 2. überarb. Aufl. 161 S., 90 Abb., 3 Tab. Verlag Chemie/Physik Verlag, Weinheim 1983. DM 78,– , 1984 .

[21]  T. Kuzel,et al.  Antibodies in the treatment of human cancer , 1994, Current opinion in oncology.

[22]  J. Condra,et al.  Bacterial expression of antibody fragments that block human rhinovirus infection of cultured cells. , 1990, Journal of Biological Chemistry.

[23]  S. Carroll,et al.  Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  W. Strohl,et al.  Developments in high cell density and high productivity microbial fermentation. , 1994, Current opinion in biotechnology.

[25]  K. Gerdes,et al.  The parB (hok/sok) Locus of Plasmid R1: A General Purpose Plasmid Stabilization System , 1988, Bio/Technology.

[26]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[27]  A. Plückthun Mono‐ and Bivalent Antibody Fragments Produced in Escherichia coli: Engineering, Folding and Antigen Binding , 1992, Immunological reviews.

[28]  M. Ptashne,et al.  Gene regulation at the right operator (OR) bacteriophage lambda. I. OR3 and autogenous negative control by repressor. , 1980, Journal of molecular biology.

[29]  G. Bennett,et al.  Modification of central metabolic pathway in escherichia coli to reduce acetate accumulation by heterologous expression of the bacillus subtilis acetolactate synthase gene , 1994, Biotechnology and bioengineering.

[30]  A. Plückthun Escherichia coli producing recombinant antibodies. , 1994, Bioprocess technology.

[31]  Erik Remaut,et al.  Tight Transcriptional Control Mechanism Ensures Stable High-Level Expression from T7 Promoter-Based Expression Plasmids , 1995, Bio/Technology.

[32]  T. Nohno,et al.  Cloning and sequencing of the Escherichia coli chlEN operon involved in molybdopterin biosynthesis , 1988, Journal of bacteriology.

[33]  Brad Snedecor,et al.  High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment , 1992, Bio/Technology.

[34]  Automatic Aseptic Sampling of Fermentation Broth , 1990, Bio/Technology.

[35]  K. Ansell,et al.  Isolation of tumor cell‐specific single‐chain Fv from immunized mice using phage‐antibody libraries and the re‐construction of whole antibodies from these antibody fragments , 1994, European journal of immunology.

[36]  B. Palsson,et al.  Metabolic Flux Balancing: Basic Concepts, Scientific and Practical Use , 1994, Bio/Technology.

[37]  T. Holak,et al.  Characterization of the linker peptide of the single‐chain Fv fragment of an antibody by NMR spectroscopy , 1993, FEBS letters.

[38]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[39]  J. Neway,et al.  Improved expression of human interleukin-2 in high-cell-density fermentor cultures of Escherichia coli K-12 by a phosphotransacetylase mutant , 1990, Applied and environmental microbiology.

[40]  A. Plückthun,et al.  The Functional Expression of Antibody Fv Fragments in Ischhuchia coli: Improved Vectors and a Generally Applicable Purification Technique , 1991, Bio/Technology.

[41]  G. Bennett,et al.  Effect of modified glucose uptake using genetic engineering techniques on high‐level recombinant protein production in escherichia coli dense cultures , 1994, Biotechnology and bioengineering.

[42]  A. Plückthun,et al.  Engineered turns of a recombinant antibody improve its in vivo folding. , 1995, Protein engineering.

[43]  H R Hoogenboom,et al.  Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. , 1991, Nucleic acids research.

[44]  T. Clackson,et al.  Making antibody fragments using phage display libraries , 1991, Nature.

[45]  M. Whitlow,et al.  Single-chain Fv proteins and their fusion proteins , 1991 .

[46]  M. Pfreundschuh,et al.  Tumor Therapy by Immune Recruitment with Bispecific Antibodies , 1995, Immunological reviews.

[47]  M. Herlyn,et al.  Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. , 1987, Cancer research.

[48]  D. Belin,et al.  Mutations that allow disulfide bond formation in the cytoplasm of Escherichia coli. , 1993, Science.

[49]  S. Lee HIGH CELL DENSITY CULTIVATION OF ESCHERICHIA COLI , 1996 .